Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Trial details
- Registry ID
- NCT04511130
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as zedenoleucel
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130 | MRKR | Phase 2 | Terminated | 2024-03-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |